ABSTRACT
Introduction
Glycaemia control is of fundamental importance in the management of diabetes mellitus (1) . landmark clinical and epidemiological studies have provided evidence that improved glycaemic control is associated with decreased incidence of diabetes-related complications including nephropathy, retinopathy, neuropathy and cardiovascular disease (23, 26, 27) . A number of strategies are available to treat type 2 diabetes, where patients often fail to achieve adequate blood glucose control with lifestyle changes recommended at diagnosis (education, diet and physical activity) and progress to therapy with a single oral antidiabetic agent (oAD). When oAD monotherapy fails, patients generally start treatment with two or more oADs. At the point where glycaemia control cannot be achieved or maintained with multiple oADs, most patients switch to exogenous insulin treatment. Premixed or biphasic insulin preparations provide both post-prandial and basal insulin requirements in a single injection. Because these insulins achieve glucose control with fewer injections compared with basal/bolus regimens they are convenient and more readily accepted by patients (29) . Premixed insulins are widely used in the treatment of type 2 diabetes, particularly considered if hbA1c > 9% (17) . in type 2 diabetes, intrapatient blood glucose variability is lower in modern insulins compared with older human insulins (3) . A number of randomized and observational studies have demonstrated the safety and efficacy of biphasic insulin aspart 30 compared with biphasic human insulin (2, 8, 13, 14, 21, 22, 28, 30) . owing to the provided evidence, the international Diabetes Federation (iDF) recommended, along with other options, premixed insulin analogue regimens for the initiation of insulin therapy (9) . the cost-effectiveness of such therapy still remains unexplored in Bulgaria.
the aim of the present study was to assess the long-term cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin in patients with type 2 diabetes in the Bulgarian setting from a third-party payer perspective.
Materials and Methods
A modelling study was carried out based on real-life data of an observational study with biphasic insulin aspart 30, therapeutic patterns for Bulgaria and local cost data (8, 12, 16, 20, 21, 24, 28, 30) . (10, 11, 12, 16, 20) . A detailed description of the model can be found in the literature (18) . the reliability of simulated outcomes has been tested, with results validated against those reported by clinical trials and epidemiological studies (19) .
Model description

Type 2 diabetes cohort
A cohort was defined with baseline demographics and baseline complications representative of patients enrolled in the iMPRoVe tM observational study ( Table 1) . Specifically, data from the subgroup of patients who previously received human premix insulin were included (21) . the long-term outcomes were calculated using a simulated cohort of 1 000 patients, each run through the model 1 000 times, of whom 57.90% were male and the mean baseline age was 57 years. the patients had a mean duration of diabetes 10.7 years at the baseline, and the mean hbA1c level was 9.21%-points. the information on tobacco and alcohol usage was Bulgaria-specific and was derived from Who (31, 32) . Data regarding cardiovascular, renal, ocular and neuropathy co-morbidities were derived from a Bulgarian cohort of 201 insulin using patients enrolled in an educational program (24) . Data regarding physiological parameter levels at the baseline were derived from a previously published cost-effectiveness analysis in the Bulgarian setting (12) .
Intervention effects the intervention effects for the simulation were based on the results of the iMPRoVe tM observational study for type 2 diabetes (Table 2) (13) . Data regarding changes in physiological parameters, apart from hbA1c and body mass index (BMi), were unavailable from the iMPRoVe tM observational study, therefore no impact of treatment was assumed for systolic blood pressure, triglycerides or lipid values.
Concomitant medications
Aspirin, statin and angiotensin-converting enzyme inhibitor (Acei) usage in the simulations was captured based on Bulgarian-specific data ( Table 3) . Data regarding aspirin, statin and Acei usage were derived from the eURoASPiRe iii survey (15) .
Costs and perspective
Bulgaria-specific cost data were used in the analysis with medical costs (pharmacy costs plus complication costs) accounted from the third-party payer perspective. indirect costs were excluded. All cost data are reported in Bulgarian leva (BGn). the cost dataset for the third-party payer perspective is shown in Table 4 . the costs of health states, modelled events, screening tests and concomitant cardiovascular medications were derived from Bulgaria-specific sources (7, 10, 11) and have been previously applied in Bulgarian-specific costeffectiveness analysis analyses (10, 20) . Pharmacy cost data (insulin only) were based on the interventions administered in the iMPRoVe tM observational study and on the official reimbursement list of the national health insurance Fund. in the simulations, type 2 diabetes patients treated with biphasic insulin aspart 30 (32.3 iU per day) incurred a cost of BGn 557.86 per annum from a third-party payer perspective. type 2 diabetes patients treated with human premix insulin (31.9 iU per day) incurred a cost of BGn 375.10 from a third-party payer perspective. the costs of self-monitoring of blood glucose and concomitant oADs were excluded from the analysis as they were not assumed to differ between any of the insulin regimens in type 2 diabetes analysis (based on the iMPRoVe tM observational study).
Health state utilities health state utility values and event disutility values were applied in the simulations (18) ( Table 5 ). Where possible, health state utilities and event disutilities were derived from the UK Prospective Diabetes Study (5), with supplementation from tengs and Wallace (25) . For disutilities for hypoglycaemic events, data from a study by currie et al. (6) were used, with each major hypoglycaemic event resulting in a disutility of -0.0118 and each minor hypoglycaemic event resulting in a disutility of -0.0035.
Time horizon
A time horizon of 30 years was used for the type 2 diabetes analysis (based on the iMPRoVe tM observational study) in order to capture all relevant long-term complications and their 
Discounting
Future clinical outcomes, in terms of life years and qualityadjusted life years (qAlYs) were discounted at a rate of 3.0% annually. Future costs were discounted at a rate of 5.0% annually.
Statistical analysis the analyses were performed using a non-parametric bootstrapping approach, in which the progression of diabetes was simulated in 1 000 patients, each run through the model 1 000 times, to calculate the mean and standard deviation of costs and life expectancy (4). Mean results of each of the 1 000 iterations in the base case analysis were used to create scatter plot diagrams comparing the differences in clinical and cost outcomes for the intervention and the comparator.
Results and Discussion
Clinical outcomes -type 2 diabetes
Life expectancy treatment with biphasic insulin aspart 30 was projected to improve life expectancy on both an undiscounted and discounted basis compared to human premix insulin ( Table   6 ). Mean undiscounted life expectancy was increased by 0.83 years over the 30-year time horizon. A life expectancy of 12.66 years was projected for patients receiving biphasic insulin aspart 30 compared to 11.83 years for patients receiving human premix insulin. Given a baseline age of 57.0 years, the mean age at death would be 69.7 years and 68.8 years in each treatment arm, respectively. When life expectancy outcomes were discounted, biphasic insulin aspart 30 was projected to improve the life expectancy by 0.51 years compared to human premix insulin (9.76 ± 0.17 versus 9.25 ± 0.16).
Quality-adjusted life expectancy treatment with biphasic insulin aspart 30 was projected to improve the quality-adjusted life expectancy compared to human premix insulin ( Table 6 ). Biphasic insulin aspart 30 was projected to improve the quality-adjusted life expectancy by 0.67 qAlYs compared to human premix insulin (6.22 ± 0.11 versus 5.55 ± 0.10).
Economic outcomes -type 2 diabetes
Cost outcomes over a 30-year time horizon, the direct costs from a third-party payer perspective were projected to be lower with biphasic insulin aspart 30 compared to those with human premix insulin. A reduction in costs of BGn 1 703 per patient was projected (BGn 15 708 ± 412 versus BGn 17 412 ± 463 per patient) ( Table 6 ).
Cost-effectiveness outcomes
As biphasic insulin aspart 30 was projected to be both more effective in terms of life years saved as well as in qAlYs and less costly than human premix insulin from a third-party payer perspective, iceRs do not need to be reported. Biphasic insulin aspart 30 may be considered dominant, in the health economics sense, compared to human premix insulin in type 2 diabetes patients in the Bulgarian setting ( Fig. 1 and Fig. 2 ). 
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Conclusions
Based on the present modelling analyses for biphasic insulin aspart 30 versus human premix insulin in type 2 diabetes, it can be concluded that biphasic insulin aspart 30 was projected to be more effective (0.67 qAlYs per patient) and less costly (BGn -1 703 per patient) from a third-party payer perspective than human premix insulin for type 2 diabetes patients in Bulgaria, and would be considered dominant.
